These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36608914)

  • 21. Genetic screening for Niemann-Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study.
    Bauer P; Balding DJ; Klünemann HH; Linden DE; Ory DS; Pineda M; Priller J; Sedel F; Muller A; Chadha-Boreham H; Welford RW; Strasser DS; Patterson MC
    Hum Mol Genet; 2013 Nov; 22(21):4349-56. PubMed ID: 23773996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma.
    Jiang X; Sidhu R; Porter FD; Yanjanin NM; Speak AO; te Vruchte DT; Platt FM; Fujiwara H; Scherrer DE; Zhang J; Dietzen DJ; Schaffer JE; Ory DS
    J Lipid Res; 2011 Jul; 52(7):1435-45. PubMed ID: 21518695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible genotype-phenotype correlations in Niemann-Pick type C patients and miglustat treatment.
    Çakar NE; Önal H
    Ideggyogy Sz; 2021 Mar; 74(3-4):139-144. PubMed ID: 33938663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease.
    Giese AK; Mascher H; Grittner U; Eichler S; Kramp G; Lukas J; te Vruchte D; Al Eisa N; Cortina-Borja M; Porter FD; Platt FM; Rolfs A
    Orphanet J Rare Dis; 2015 Jun; 10():78. PubMed ID: 26082315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Niemann-Pick Type C1.
    Völkner C; Liedtke M; Hermann A; Frech MJ
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normalization of Hepatic Homeostasis in the
    Munkacsi AB; Hammond N; Schneider RT; Senanayake DS; Higaki K; Lagutin K; Bloor SJ; Ory DS; Maue RA; Chen FW; Hernandez-Ono A; Dahlson N; Repa JJ; Ginsberg HN; Ioannou YA; Sturley SL
    J Biol Chem; 2017 Mar; 292(11):4395-4410. PubMed ID: 28031458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased Regenerative Capacity of the Olfactory Epithelium in Niemann-Pick Disease Type C1.
    Meyer A; Wree A; Günther R; Holzmann C; Schmitt O; Rolfs A; Witt M
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28383485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A human iPSC-derived inducible neuronal model of Niemann-Pick disease, type C1.
    Prabhu AV; Kang I; De Pace R; Wassif CA; Fujiwara H; Kell P; Jiang X; Ory DS; Bonifacino JS; Ward ME; Porter FD
    BMC Biol; 2021 Oct; 19(1):218. PubMed ID: 34592985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of FDA-Approved Drugs as a Therapeutic Approach for Niemann-Pick Disease Type C1 Using Patient-Specific iPSC-Based Model Systems.
    Völkner C; Pantoom S; Liedtke M; Lukas J; Hermann A; Frech MJ
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts.
    Newton J; Hait NC; Maceyka M; Colaco A; Maczis M; Wassif CA; Cougnoux A; Porter FD; Milstien S; Platt N; Platt FM; Spiegel S
    FASEB J; 2017 Apr; 31(4):1719-1730. PubMed ID: 28082351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy.
    Yu D; Swaroop M; Wang M; Baxa U; Yang R; Yan Y; Coksaygan T; DeTolla L; Marugan JJ; Austin CP; McKew JC; Gong DW; Zheng W
    J Biomol Screen; 2014 Sep; 19(8):1164-73. PubMed ID: 24907126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
    Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
    Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microarray expression analysis and identification of serum biomarkers for Niemann-Pick disease, type C1.
    Cluzeau CV; Watkins-Chow DE; Fu R; Borate B; Yanjanin N; Dail MK; Davidson CD; Walkley SU; Ory DS; Wassif CA; Pavan WJ; Porter FD
    Hum Mol Genet; 2012 Aug; 21(16):3632-46. PubMed ID: 22619379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholestane-3β, 5α, 6β-triol: Further insights into the performance of this oxysterol in diagnosis of Niemann-Pick disease type C.
    Cooper JA; Church HJ; Wu HY
    Mol Genet Metab; 2020 May; 130(1):77-86. PubMed ID: 32178982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
    Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice.
    Williams IM; Wallom KL; Smith DA; Al Eisa N; Smith C; Platt FM
    Neurobiol Dis; 2014 Jul; 67():9-17. PubMed ID: 24631719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Brain-Specific Treatment Effects in NPC1 Disease by Focusing on Cellular and Molecular Changes of Sphingosine-1-Phosphate Metabolism.
    Gläser A; Hammerl F; Gräler MH; Coldewey SM; Völkner C; Frech MJ; Yang F; Luo J; Tönnies E; von Bohlen Und Halbach O; Brandt N; Heimes D; Neßlauer AM; Korenke GC; Owczarek-Lipska M; Neidhardt J; Rolfs A; Wree A; Witt M; Bräuer AU
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect.
    Nadjar Y; Hütter-Moncada AL; Latour P; Ayrignac X; Kaphan E; Tranchant C; Cintas P; Degardin A; Goizet C; Laurencin C; Martzolff L; Tilikete C; Anheim M; Audoin B; Deramecourt V; De Gaillarbois TD; Roze E; Lamari F; Vanier MT; Héron B
    Orphanet J Rare Dis; 2018 Oct; 13(1):175. PubMed ID: 30285904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of serum cholestane-3β,5α,6β-triol by gas chromatography-mass spectrometry for identification of Niemann-Pick type C (NPC) disease.
    Kannenberg F; Nofer JR; Schulte E; Reunert J; Marquardt T; Fobker M
    J Steroid Biochem Mol Biol; 2017 May; 169():54-60. PubMed ID: 26940355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine profile and cholesterol levels in patients with Niemann-Pick type C disease presenting neurological symptoms: in vivo effect of miglustat and in vitro effect of N-acetylcysteine and coenzyme Q10.
    Hammerschmidt TG; Donida B; Faverzani JL; Moura AP; Dos Reis BG; Machado AZ; Kessler RG; Sebastião FM; Reinhardt LS; Moura DJ; Vargas CR
    Exp Cell Res; 2022 Jul; 416(2):113175. PubMed ID: 35487270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.